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Introduction
Neural tube closure defects (NTDs) are usually under-
stood to include lumbosacral myelomeningocele, anen-
cephaly (including exencephaly, cranioraschisis, and 
acrania), and encephalocele together with a variety of 
rarer severe defects.1,2 They are responsible for an esti-
mated 300 000 major congenital anomalies worldwide 
annually, and approximately 88 000 deaths and 8.6 mil-
lion disability-adjusted life years across the globe.3 They 
are a major cause of death in small children under 5 
years of age.
A number of risk factors have been identified for 
NTDs including maternal obesity, diabetes, especially 
poorly controlled insulin-dependent diabetes, vitamin 
B
12
 deficiency, some genetic anomalies of the folic acid 
metabolism pathway, and the use of some drugs.4-6 
Gestational use of a variety of drugs has been associated 
with increased rates of NTDs including anticonvulsants 
(carbamazepine, phenytoin, valproic acid), antidepres-
sants (sertraline, fluoxetine), mood stabilizers (lithium), 
and folic acid antagonists (methotrexate, trimethoprim).7,8 
Hence, these drugs are relatively contraindicated during 
parturition and are only used in selected cases where it is 
felt that the benefits outweigh the known risks.
Dietary supplementation with folic acid has been 
shown to dramatically reduce the incidence of NTDs by 
up to 72% in 3 randomized controlled trials from the 
United States, China, and Europe.9-11 This has rightly 
been hailed as one of the major neonatal public health 
894798 GPHXXX10.1177/2333794X19894798Global Pediatric HealthReece and Hulse
research-article2019
1University of Western Australia, Crawley, Western Australia, 
Australia
2Edith Cowan University, Joondalup, Western Australia, Australia
Corresponding Author:
Albert Stuart Reece, 39 Gladstone Road, Highgate Hill, Brisbane, 
Queensland, Australia. 
Email: stuart.reece@bigpond.com
Cannabis Consumption Patterns Explain 
the East-West Gradient in Canadian 
Neural Tube Defect Incidence: An 
Ecological Study
Albert Stuart Reece, MBBS (Hons), FRCS (Ed), FRCS (Glas), FRACGP, MD1,2   
and Gary Kenneth Hulse, BBSc (Hons), MBSc, PhD1,2
Abstract
While a known link between prenatal cannabis exposure and anencephaly exists, the relationship of prenatal 
cannabis exposure with neural tube defects (NTDs) generally has not been defined. Published data from Canada 
Health and Statistics Canada were used to assess this relationship. Both cannabis use and NTDs were shown to 
follow an east-west and north-south gradient. Last year cannabis consumption was significantly associated (P < 
.0001; cannabis use–time interaction P < .0001). These results were confirmed when estimates of termination 
for anomaly were used. Canada Health population data allowed the calculation of an NTD odds ratio) of 1.27 
(95% confidence interval = 1.19-1.37; P < 10−11) for high-risk provinces versus the remainder with an attributable 
fraction in exposed populations of 16.52% (95% confidence interval = 12.22-20.62). Data show a robust positive 
statistical association between cannabis consumption as both a qualitative and quantitative variable and NTDs on 
a background of declining NTD incidence. In the context of multiple mechanistic pathways these strong statistical 
findings implicate causal mechanisms.
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triumphs of our time and places NTDs fairly in the group 
of largely preventable disorders. Unfortunately, their 
rate continues to be very high in some of the less devel-
oped parts of the world, with rates exceeding 50 cases/10 
000 live births in parts of India, Africa, the Middle East, 
and up to 200/10 000 in some of the northern regions of 
China.3,12,13
The practice of therapeutic early termination of preg-
nancy for anomaly (ETOPFA) has also been rising from 
1980 to the present time in many places including the 
Canadian province of British Colombia,14 Sweden,15 
Europe,16 the United States,17 and Western Australia18 
and is thought to be the primary cause of the falling rates 
of NTDs in various registries.16-19 The issue is very 
important in relation to NTDs as ETOPFA rates of 80% 
have been reported for anencephaly, 46% for spina 
bifida, and 56% for encephalocoele in Canada in recent 
years.1 Therefore, epidemiological studies that consider 
data for live births may miss 80% to 90% of the true 
defect rate in some congenital anomaly registries.18
The incidence of NTDs in Canada as a function of 
births (= stillbirths plus live births but excluding 
ETOPFAs) dropped from 1989 to 2007 from a mean of 
11.1 to 4.1/10 000 births.20,21
It is said to be difficult to differentiate the relative 
contribution of dietary folic acid supplementation com-
pared with ETOPFA as an explanation for the falling 
rates of NTDs in Canada.20
Interestingly, several papers have been issued by the 
National Birth Defects Prevention Network (NBDPN) 
of the Centers for Disease Control and Prevention 
(CDC) Atlanta, Georgia, which have noted that the rate 
of anencephaly is almost doubled after cannabis expo-
sure.22,23 It is well known that cannabis is the most com-
monly used illicit drug with 183 million individuals 
worldwide reporting its use.24-26 Indeed, 161 000 preg-
nant women in the United States reported cannabis use 
while pregnant,27-29 24% of pregnant Californian teen-
agers tested positive for cannabinoids,30 and indeed in 
69% of cases cannabis dispensaries in Colorado recom-
mend the use of cannabis to pregnant mothers.31 
Cannabis use by females in Canada rose from 7% in 
2013 to 10% in 2015.32 Canadian data show that 72% 
most of the cannabis users who have used cannabis in 
the last year have used it in the previous 3 months.33 All 
4 of the National Cannabis Surveys conducted by 
Statistics Canada in 2018 show that cannabis is used 
overwhelmingly and disproportionately by young adults 
in the reproductive age group.33 Cannabis edibles are 
used by 41% of females in the preceding 3 months com-
pared with only 26% of males, representing a 1.57-fold 
higher rate of use.32 Hence, cannabis use during preg-
nancy is a major public health issue. And as noted above, 
anencephalus is one of the classical NTDs. These data 
broaden the context of the cannabis-anencephalus link, 
which has been reported several times by the CDC from 
a closely constrained discussion of anencephalus alone 
and places it in the wider context of NTDs generally 
since they all share a similar pathophysiology in terms 
of the zipper-like closure of the neural tube during early 
fetal development.
This sets up an interesting dichotomy of population 
health forces in the child-bearing population with folic 
acid augmentation on the one hand tending to reduce 
NTDs and drug use on the other tending to increase them.
Canada forms a promising nation in which to study 
the public health implications of these issues as data per-
taining to both NTD incidence and cannabis use has been 
made available. The Canadian government recently pub-
lished large reviews of the national experience of NTDs 
and a number of surveys document drug use by the 
Canadian populace at the provincial level. Indeed, one 
survey suggests a 3-fold variation in cannabis use across 
Canadian provinces from 11% in Quebec to 33% in 
Nunavut.34 Significant variance in each parameter sepa-
rately naturally raises the issue of the extent to which the 
observed variation in cannabis use accounts for the 
observed variation in NTD incidence. This forms an 
ideal opportunity to study these modern neonatal epide-
miological-ecological trends at the associational level.
This study was performed to examine the relation-
ship between cannabis use and NTD incidence to deter-
mine if the causal relationship previously identified by 
the National Birth Defects Prevention Network 
(NBDPN) of the CDC in relation to anencephaly22,23 
could be identified in the national teratological profile of 
NTDs in Canada.
Methods
Data Sources
Data on neural tube defect rates excluding terminations 
for defects by province was taken from a Canadian gov-
ernment publication (Tables B3.2A, B3.2B, B3.2C, 
pages 106-107, in Public Health Agency of Canada, 
Health Canada35). Data for NTD rates by province 
including termination for defects for the same 3 periods 
was taken from Supplementary Table 2 in De Wals et al.1
Data on cannabis use were taken from 2 sources. The 
University of Waterloo performed a commissioned sur-
vey of Canadian provinces for Canada Health.36 Statistics 
Canada has also performed surveys of Canadian canna-
bis use by province and territory.34 The survey for the 
second quarter of 2018 had complete data for all Canadian 
provinces and territories.34
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Cannabis Use Group Allocation
The 5 highest provinces in the University of Waterloo 
dataset were assigned to high cannabis states, namely, 
Newfoundland, Prince Edward Island, Nova Scotia, 
Manitoba, and Saskatchewan. Statistics Canada indi-
cated that the provinces of Newfoundland, Nova Scotia, 
and Ontario were in the high-use group together with the 
territories of Nunavut, Northwest, and Yukon.
ETOPFA Estimation
The existence of a dataset for Canadian NTDs with 
ETOPFAs included1 and one without20 covering very 
similar time periods clearly provide an opportunity to 
derive the applicable ETOPFA rates by period from the 
difference between these 2 rates. The arithmetical details 
for these calculations are shown in Supplementary Table 
1 (available online). From these data one is able to 
derive an average ETOPFA rate in each of the 3 periods. 
Since the data for Prince Edward Island is incomplete in 
Health Canada,20 this data point was omitted in calculat-
ing the average for the 3 periods.
Statistics
Data were processed in “R” v3.5.2 and “R Studio” 
v1.1.463 from the Central “R” Archive Network. Graphs 
and maps were drawn in “ggplot”. Data were log trans-
formed to improve compliance with normality assump-
tions based on the results of the Shapiro-Wilks test. Risk 
ratios were calculated using the “epiR” package. P < 
.05 was considered significant.
Ethical Approval
Ethical approval for this study was received from the 
Human Research Ethics Committee (HREC) of the 
Southcity Medical Centre and the University of Western 
Australia. The approval from Southcity Medical Centre 
was dated May 31, 2018, and the approval from the 
University of Western Australia was dated April 1, 2019, 
and numbered RA/4/20/4724.
Results
A total of 3919 cases of NTDs were recorded from 1991 
to 2007 among 6 092 250 live births in the Health 
Canada Reference report.35
Folic acid augmentation into the grain staples in Canada 
commenced in 1997 and became mandatory in September 
2000. Hence, the NTD incidence data across this period 
naturally falls into 3 periods: before, during, and after this 
transitional period. Figure 1 maps the distribution of can-
nabis use in 2015 and of NTDs in the 3 periods from 1991 
to 1996, 1997 to 2000, and 2001 to 2007 across Canada.
One notes that these datasets relate to differing time 
periods. While this is an issue, survey data of cannabis 
use prevalence across Canada is very rare and this 
University of Waterloo survey is the earliest dataset we 
were able to identify. It is used here as we feel that due 
to spatiotemporal autocorrelation whatever cannabis use 
was at an earlier time period was related in some manner 
to cannabis use at this earliest documented period.
Figure 2A presents a scatterplot of the NTD rate by 
time. Data have been horizontally “jittered” to prevent 
overplotting, and data points are positioned about the 
midpoint of the 3 intervals: 1991 to 1996, 1997 to 2000, 
and 2001 to 2007. The highest levels of NTD s occurred 
in Newfoundland and Nova Scotia in the 1991 to 1996 
period, with NTD rates of 30.5 and 19.8/10 000, respec-
tively. The obvious downward trend over time is clear.
Figure 2B re-plots these data after dividing the prov-
inces into high and low cannabis use areas ranked from 
the University of Waterloo survey of 2014-2015.36 A 
clear separation of the high and low cannabis use prov-
inces is apparent. Figure 2C does the same thing follow-
ing the assignment distribution of Statistics Canada for 
2018.34 One notes in Figure 2B and C that the incidence 
of NTDs in both high- and low-prevalence provinces is 
similar in 2004. This appears to be due to a greater 
reduction in the high cannabis use provinces and territo-
ries than in the low prevalence areas; however, in the 
absence of accurate ETOPFA data one cannot be sure if 
an increase in ETOPFA practice might also have been 
implicated. Again Figure 2C shows a clear separation of 
the 2 regression lines. This is quantified in the Table 1 
where cannabis use in 2015 is shown to be significant (P 
= .0063), and for cannabis use in 2018 both cannabis 
use itself, and cannabis use in interaction with time are 
shown to be highly significant (both P < .0001).
Figure 3 graphs the NTD rates against (1) last year 
cannabis use; (2) age of initiation of cannabis use; and (3) 
an index that is derived as the percent of cannabis use 
divided by the age of initiation for the University of 
Waterloo data.36 Close examination of panel A shows that 
the scales in each of the 3 graphs is falling, consistent 
with the drop in overall levels of NTDs by each period. In 
the middle panels it appears that rising age of initiation is 
associated with falling rates of NTDs; however, these 
changes are not significant. Results for the Cannabis 
Index parallel those for the percent cannabis use.
These various effects are quantified in Table 1. One 
notes that when the whole dataset is considered together 
there are many highly significant terms involving can-
nabis use relating to group assignment, last month and 
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last year cannabis use, age of initiation, and the cannabis 
index all in 2015, and cannabis use in 2018 both as a 
qualitative variable by way of group assignment and as 
a quantitative continuous variable.
As noted above, Gilbert et al20 the Canadian provin-
cial NTD data without ETOPFAs and1 lists the same 
dataset with ETOPFAs included. The difference in these 
2 rates therefore logically represents the rate of ETOPFA 
for NTDs in the various listed Canadian provinces. Data 
from external sources indicate that the NTD rate has 
been relatively constant and stable in Canada prior to 
and after the transitional period of the introduction of 
folic acid.20,21 Supplementary Table 1 provides the arith-
metical details of how these calculations were per-
formed. Informatively one notes that the average 
ETOPFA rate in the 3 periods rose from 32.56% in the 
first period, to 35.05% and 43.74% in the second and 
third periods, respectively. These average rates were 
then used to estimate an NTD rate inclusive of ETOPFAs 
for Saskatchewan, Ontario, and New Brunswick, whose 
data were not provided.1
These estimates of the NTD rates including the 
ETOPFA rate were then regressed against cannabis use 
variables with the highly significant results (Table 2).
Data presented Public Health Agency of Canada, 
Health Canada,35 allow one to calculate the birth popu-
lations at risk. When populations were divided based on 
the University of Waterloo dataset it is calculated that 
1096 of 1 423 104 births had NTDs in high-risk states 
and 2823 of 4 667 146 births in low cannabis using 
states had NTDs, which provides a point estimate for 
the odds ratio (OR) of 1.274 (95% confidence interval 
[CI] = 1.19-1.37, P = 9.19 × 10−12). This is equivalent 
to an attributable risk in the exposed population of 
16.52% (95% CI = 12.22% to 20.62%). When prov-
inces were assigned based on the Statistics Canada 
grouping, very similar results were obtained (OR = 1.25, 
95% CI = 1.16-1.35, P = 2.47 × 10−9), attributable 
Figure 1. Maps of cannabis and neural tube defect (NTD) distribution. (A) Last year cannabis use rates by province, 2015. (B) 
NTD rates by province from 1991 to 1996. (C) NTD rates by province from 1997 to 2000. (D) NTD rates by province from 
2001 to 2007.
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risk in exposed population of 16.35% (95% CI = 
11.40% to 21.01%).
Discussion
This study shows that, notwithstanding the overall posi-
tive response of the maternal population to folic acid 
supplementation there are statistical associational sig-
nals within the Canadian perinatal teratological data on 
NTDs indicating a positive relationship to cannabis use. 
Highly statistically significant relationships between 
NTD incidence both in relation to birth defect rates, and 
also after correction for estimates of the effect of early 
abortions for defects were studied, and the relationship 
Figure 2. Neural tube defect rates over time. (A) Neural tube defect rates over time overall data. (B) Neural tube defect 
rates over time by high and low cannabis use provinces (2015 data). (C) Neural tube defect rates over time by high and low 
cannabis use provinces (2018 data).
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remained robust to various categorization protocols, and 
various metrics of cannabis use.
An OR of 1.27 (95% CI = 1.19-1.37) was calculated 
for high compared with low cannabis use provinces with 
an attributable risk in high cannabis use provinces of 
16.52% (95% CI = 12.22% to 20.62%).
As such it would appear from this analysis that the 
different patterns in cannabis consumption across 
Canada may well explain the east-west gradient of 
NTDs, which has long been known and has long been of 
interest to neonatal epidemiologists.
Calculations performed in the present work indicate 
that the rate of ETOPFA across Canada increased 
between 1991 and 2007 from a mean of 32.3% to 43.2%. 
The detailed analysis of NTD rates in Canada of De 
Wals et al1 included ETOPFA data and showed that a 
reduction in NTD rate could be demonstrated when 
ETOPFA data were included. However, Gilbert and col-
leagues,20 writing several years later, presumably with 
access to much of the data of the earlier study, felt that 
they could not say with any certainty how much of the 
decline in NTD rates were due to rising ETOPFA rates 
and how much was due to folate supplementation. The 
present work does not have access to sufficient data to 
comment on this interesting dilemma.
The greatest drop in Canada NTD rates occurred in 
high-risk provinces after folate supplementation.1 In 
Australia this also happened and a dramatic drop in 
indigenous Australian Aborigines was also documented 
following folate supplementation.37
Beyond the fascinating pattern of epidemiology, 
which has been uncovered by the above statistical calcu-
lations, one of the most intriguing aspects of this study is 
the obvious gaps in the data in relation to the Canadian 
Table 1. Linear Regressions of Live Born Neural Tube Defect (NTD) Rates.
Input Parameters
Parameter Analyses Model Parameters
Estimate SE t Value Pr(>|t|) Adjusted R2 F df P
NTD rate by cannabis use by era  
Era 1  
 Cannabis use (annual) 0.0509 0.0353 1.442 .1925 0.1189 2.079 1.7 .1925
Era 2  
 Cannabis use (annual) 0.0507 0.0096 5.293 .0018 0.7942 28.02 1.6 .0018
Era 3  
 Cannabis use (annual) 0.1365 0.0614 2.225 .0678 0.3607 4.949 1.6 .0678
NTD rate by cannabis use by time and 
parameter
 
Rate ~ year * group (2015)  
 Year −0.0897 0.0123 −7.312 .0000 0.6986 32.29 2.25 1.2E-07
 Group 0.3174 0.1064 2.984 .0063  
Rate ~ year * cannabis use (annual)  
 Year −0.0826 0.0128 −6.470 .0000 0.6925 28.03 2.22 8.9E-07
 Cannabis use (annual) 0.0447 0.0135 3.311 .0032  
Rate ~ year * cannabis use (month)  
 Year −0.0836 0.0152 −5.506 .0000 0.6369 19.41 2.19 2.6E-05
 Cannabis use (month) 0.0449 0.0172 2.611 .0172  
Rate ~ year * age initiation  
 Year: age initiation −0.0060 0.0011 −5.532 .0000 0.5788 15.43 2.19 .0001
 Age initiation 11.8219 2.1569 5.481 .0000  
Rate ~ year * cannabis index  
 Year −0.0850 0.0140 −6.060 .0000 0.6714 22.46 2.19 9.9E-06
 Cannabis index 0.5046 0.1998 2.526 .0206  
Rate ~ year * group (2018)  
 Year −0.1301 0.0213 −6.108 .0000 0.7122 23.27 3.24 2.8E-07
 Group 110.5561 51.4954 2.147 .0421  
 Year: group −0.0552 0.0258 −2.141 .0426  
Rate ~ year * cannabis use (3 months, 2018)  
 Cannabis use (3 months) 11.1933 1.5533 7.206 .0000 0.6753 29.08 2.25 3.0E-07
 Year: cannabis use (3 months) −0.0056 0.0008 −7.179 .0000  
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territories. The maps in Figure 1 clearly show that the 
data tabled provide no data whatsoever for the territories 
of Nunavut, Yukon, and Northwest and these fascinating 
circumpolar parts of arctic Canada remain undefined in 
this regard.
Other reports define high rates of total congenital 
anomalies, congenital heart disease, Down’s syndrome, 
orofacial clefts, and gastroschisis in Nunavut, most of 
which are statistically significantly elevated above the 
national rates,35 together with high rates of premature 
birth, infant mortality, and post-neonatal death elevated 
3 times and more above the national average.21 One 
might realistically conjecture, therefore, that when the 
numbers become available high rates of NTD may also 
be shown in such remote northern regions. Nunavut area 
is also described as having very high rates of chronic 
hunger, homelessness, poverty, violent crime, suicide, 
substance abuse, and sexually transmissible disease.38 
Figure 3. Neural tube defect (NTD) rates by cannabis metrics. (A) NTD rate by last year cannabis use percentage. (B) NTD 
rates by age of cannabis initiation. (C) NTD rates by cannabis index (= last year cannabis use/age of initiation).
8 Global Pediatric Health
Clearly untangling this complex etiological web of 
potential causes in the challenging climate of the arctic 
north among a scattered population is a task that would 
require considerable resources and dedication.
In considering this bewildering array of complex 
psychosocial adversity, the present studies would 
strongly suggest that cannabis should not be forgotten as 
a potential cause. Indeed it is reported that the use of 
cannabis by many adult age groups is virtually holoen-
demic in this region.39 It would seem to us that filling in 
these datasets would have far-reaching implications 
potentially well beyond those relating to circumpolar 
health.
Given robust previous results from leading US 
schools of public health linking increasingly liberal leg-
islative paradigms with increased cannabis use,40 the 
present findings must raise concerns that increased can-
nabis use in Canada related to cannabis legalization in 
that nation may be shown in time to be associated with 
unforeseen trends in NTDs among other congenital 
defects.
While the effect demonstrated in this article is at the 
level of a statistical association it achieves considerable 
importance in light of the numerous documented mecha-
nistic pathways linking cannabis with multiple mecha-
nisms of teratogenesis. Space precludes a detailed 
exploration of this subject in this forum, but the follow-
ing comments may form a useful point of departure for 
future workers. It is known that NTDs represent failure 
of closure of the embryonic neural tube usually at its 
upper and lower ends. Therefore, pathways that impede 
cell growth may be implicated. Cannabis has been 
shown on proteomic screen to interfere with actin and 
tubulin synthesis.41 Actin is a key molecule for the 
cytoskeleton involved in cell signaling and cell shape 
change in cell division and cell migration. Tubulin is the 
monomer from which microtubules form, which form 
the rails of cell division. Cannabis has long been known 
to test positive in the micronuclear assay and this is 
believed to be on the basis of its interference with micro-
tubular function.42-44 Cannabis also perturbs notch sig-
naling, which is a key morphogen for both embryonic 
neuraxis and cardiovascular formation.45,46
Closure of the neural tube initiates at the level of the 
human hindbrain on post-fertilization day 22 and pro-
ceeds bidirectionally cephalad and caudal. It also initi-
ates from the rostral neuropore bidirectionally. Closure 
occurs at the anterior neuropore on day 24 and over the 
sacrum on day 26.2 Over 200 genes involved in path-
ways such as cytoskeletal regulation, cell proliferation, 
transcriptional control, one carbon transfer, epigenetic 
regulation, and interference with sphingosine phosphate 
metabolism (by the fungal metabolite fumonisin) have 
been implicated.2 Molecular signaling pathways includ-
ing hedgehog, bone morphogenetic proteins, and reti-
noid signaling have also been implicated.2 Interestingly, 
cannabinoids interact with and inhibit each of these 
major pathways with cannabinoid-hedgehog,47 cannabi-
noid-bone morphogenetic proteins (both directly and by 
vanilloid mediation),48 and cannabinoid-retinoid inter-
actions49-52 having been previously described.
Cannabis adversely affects robo/slit signaling, which 
is a key receptor ligand pair that has major dual actions 
in brain and nerve formation.53 Low levels of robo are 
key to the hyperproliferation of subventricular zone 
embryonic neuroblasts and formation of the large 
human neocortex.54,55 And robo/slit pairs also form key 
guidance signals for both axon guidance and vascular 
Table 2. Linear Regressions of Total NTD Rates Including Estimated ETOPFA Rates.
Input Parameters
Parameter Analyses Model Parameters
Estimate SD t Value Pr(>|t|) Adjusted R2 F df P
Rate ~ year * cannabis use, 2015  
 Cannabis use (annual) 7.2497 1.4232 5.094 .0000 0.5459 16.03 2.23 4.4E-05
 Year: cannabis use (annual) −0.0036 0.0007 −5.069 .0000  
Rate ~ year * age initiation  
 Age of initiation 10.0201 2.3703 4.227 .0004 0.4210 9.00 2.20 .0016
 Year: age of initiation −0.0050 0.0012 −4.242 .0004  
Rate ~ Year * cannabis index  
 Cannabis index 106.0551 22.5859 4.696 .0001 0.5427 14.05 2.20 .0002
 Year: cannabis index −0.0528 0.0113 −4.672 .0001  
Rate ~ year * cannabis use, 2018  
 Cannabis use (3 months) 9.4836 1.6749 5.662 .0000 0.5282 16.67 2.26 2.2E-05
 Year: cannabis use (3 months) −0.0047 0.0008 −5.650 .0000  
Abbreviations: NTD, neural tube defect; ETOPFA, early termination of pregnancy for anomaly.
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sprouting and direction.46 Slit2 is also a tumor suppres-
sor.56 Cannabis interferes with neurexin and neuroligin 
synthesis and signaling this receptor ligand pair forms 
the basic scaffold of the neuronal synapse and plays a 
key role in synaptic formation and organization.57,58 
Cannabinoids have numerous immune interactions and 
immune activity is a key sculptor of the embryonic and 
developing neuraxis.59 Cannabis has widespread epigen-
etic actions with effects particularly on the brain, 
immune systems, and sperm.60-64 Interestingly, folic acid 
also works epigenetically by acting as a methyl donor in 
N-methylation reactions for DNA and histones via 
S-adenosyl-methionine.65 Cannabis acts via at least 7 
receptors in the body.59 The type 1 cannabinoid receptor 
(CB1R) is widely distributed in many tissues including 
brain from very early in fetal life and is thus likely to 
have downstream consequences.66,67 Cannabinoid sig-
naling via CB1Rs is a key regulator of cerebral micro-
vascular function and is directly responsible for the 
BOLD signal seen on functional magnetic resonance 
imaging with neuronal activity.68 The brain’s microvas-
culature forms a key regulator of brain neurogenic 
niches.67,69-71 Brain formation and circuit wiring is 
highly dependent on neuronal activity. In that cannabis 
is well known to suppress neuronal firing, this implies 
that it will have major morphological and long-term 
developmental consequences. And CB1Rs are also 
found at moderate density in bone.72,73
Cannabinoids are also highly toxic to eggs and sper-
matids.74-78 Both ova and mature spermatids lack most 
of the molecular genetic machinery to repair DNA dam-
age. The very real possibility exists therefore that dam-
age to nonrenewable ova may be long term or even 
permanent.
Interestingly, prenatal cannabis exposure was 
recently shown to affect the methylation status of 4 
genes involved in Wnt signaling, which is a major body 
morphogen, namely, 3A, 5A, 9A, and 10A.63 Wnt signal-
ing has been shown to control closure of the anterior 
neuropore,79 a finding which may relate directly to the 
elevated risk of encephalocoele which has been linked 
epidemiologically with prenatal cannabis use.80
In summary, while it is often said that cannabis is a 
“natural product,” the reality is that it has been well det-
monstrated in botanical science that cannabinoids form 
part of a potent plant defense mechanism against both 
other plants—including other cannabis plants—and ani-
mals.81,82 That is to say cannabinoids are in fact a natural 
plant poison.
The strengths of this study are that it takes national 
and publicly available data from 2 leading sources, uses 
2 metrics of cannabis consumption and 2 categorization 
protocols to conduct a secondary analysis of national 
data at the provincial level. The analyses are simple and 
straightforward and are clearly in close accordance with 
the demonstrated graphical and map displays. Many of 
the probability levels reported are at high or very high 
levels of statistical significance.
Most of the limitations of this study relate to its 
design as an ecological secondary analysis. Individual 
case-control data were not available to this study. 
Territory congenital anomaly and covariate data are not 
yet publicly available for Canada, and that is likely to be 
some of the most important data of all. It has not been 
possible here to take into account any of the covariates 
such as race, diet, and education that might be studied in 
a larger investigation as these data were not available for 
our analysis. Given that much of the north of Canada is 
very cold and dark most of the year, dietary factors may 
be very important, as may genetic allele frequencies of 
native and indigenous people groups. From a method-
ological perspective, it is important to note that to sim-
ply add in covariates such as ethnicity, in the presence of 
well-documented and adequately substantiated major 
racial differences in the prevalence of drug use, is to 
make an opposite error of over-controlling and in fact 
erroneously regressing out important differences. In this 
regard, advanced statistical techniques such as general-
ized 2-stage regression with appropriate instrumental 
variables may be a more versatile tool. Ideally geospa-
tiotemporal models at high geographic resolution, which 
take into account all of these various factors using 
appropriate adjustment and advanced statistical meth-
ods, may be most appropriate for future investigations 
once a sufficient dataset can be assembled. ETOPFA 
data were not available longitudinally, which would be 
preferable to conduct a formal study. Notwithstanding 
this we see our work as important and path finding and 
showing the way for future more detailed and more 
complex studies both in Canada and internationally.
Conclusion
The epidemiological relationship that we have demon-
strated between cannabis use and NTD incidence within 
the context of falling overall NTD rates is interesting, 
provocative, and intriguing. The ecological association is 
seen in both live born statistics and also in estimates of 
the complete dataset including ETOPFA data, which are 
important to complete the holistic picture of the true epi-
demiological incidence of NTDs; it is seen with 2 met-
rics of cannabis use and with 2 categorization algorithms 
for classifying the provinces. Our work is consistent with 
earlier reports from the CDC in the United States relating 
to the links between cannabis use and the doubled inci-
dence of anencephaly. In the context of multiple known 
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molecular mechanistic pathways such compelling and 
robust statistical associations necessarily implicate cau-
sality. We would be keen to see this relationship studied 
in other places along with the all-important applicable 
ETOPFA and covariate data preferably in case-control 
designs. The arctic regions of Canada are almost cer-
tainly of particular importance to the neonatal epidemiol-
ogy of NTDs with far-reaching and likely global 
implications and require further detailed investigation.
Author Contributions
ASR: Contributed to conception and design; contributed to 
acquisition, analysis, and interpretation; drafted manuscript; 
critically revised manuscript; gave final approval; agrees to 
be accountable for all aspects of work ensuring integrity and 
accuracy.
GKH: Contributed to conception; contributed to interpreta-
tion; critically revised manuscript; gave final approval; agrees 
to be accountable for all aspects of work ensuring integrity and 
accuracy.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with 
respect to the research, authorship, and/or publication of this 
article.
Funding
The author(s) received no financial support for the research, 
authorship, and/or publication of this article.
ORCID iD
Albert Stuart Reece  https://orcid.org/0000-0002-3256-720X
Supplementary Material
Supplemental material for this article is available online.
References
 1. De Wals P, Tairou F, Van Allen MI, et al. Reduction in 
neural-tube defects after folic acid fortification in Canada. 
N Engl J Med. 2007;357:135-142.
 2. Copp AJ, Adzick NS, Chitty LS, Fletcher JM, Holmbeck 
GN, Shaw GM. Spina bifida. Nat Rev Dis Primers. 
2015;1:15007.
 3. Zaganjor I, Sekkarie A, Tsang BL, et al. Describing the 
prevalence of neural tube defects worldwide: a systematic 
literature review. PLoS One. 2016;11:e0151586.
 4. Shaw GM, Quach T, Nelson V, et al. Neural tube defects 
associated with maternal periconceptional dietary intake 
of simple sugars and glycemic index. Am J Clin Nutr. 
2003;78:972-978.
 5. Shaw GM, Todoroff K, Velie EM, Lammer EJ. Maternal 
illness, including fever and medication use as risk factors 
for neural tube defects. Teratology. 1998;57:1-7.
 6. Yazdy MM, Liu S, Mitchell AA, Werler MM. Maternal 
dietary glycemic intake and the risk of neural tube defects. 
Am J Epidemiol. 2010;171:407-414.
 7. Hernandez-Diaz S, Werler MM, Walker AM, Mitchell 
AA. Neural tube defects in relation to use of folic 
acid antagonists during pregnancy. Am J Epidemiol. 
2001;153:961-968.
 8. Lambie DG, Johnson RH. Drugs and folate metabolism. 
Drugs. 1985;30:145-155.
 9. Prevention of neural tube defects: results of the Medical 
Research Council Vitamin Study. MRC Vitamin Study 
Research Group. Lancet. 1991;338:131-137.
 10. Berry RJ, Li Z, Erickson JD, et al. Prevention of neural-
tube defects with folic acid in China. China-US collabora-
tive project for neural tube defect prevention. N Engl J 
Med. 1999;341:1485-1490.
 11. Czeizel AE, Dudas I. Prevention of the first occurrence of 
neural-tube defects by periconceptional vitamin supple-
mentation. N Engl J Med. 1992;327:1832-1835.
 12. Blencowe H, Kancherla V, Moorthie S, Darlison MW, 
Modell B. Estimates of global and regional prevalence of 
neural tube defects for 2015: a systematic analysis. Ann N 
Y Acad Sci. 2018;1414:31-46.
 13. Kancherla V, Black RE. Historical perspective on folic 
acid and challenges in estimating global prevalence of 
neural tube defects. Ann N Y Acad Sci. 2018;1414:20-30.
 14. Van Allen MI, Boyle E, Thiessen P, et al. The impact of 
prenatal diagnosis on neural tube defect (NTD) pregnancy 
versus birth incidence in British Columbia. J Appl Genet. 
2006;47:151-158.
 15. Nikkila A, Rydhstrom H, Kallen B. The incidence of 
spina bifida in Sweden 1973-2003: the effect of prenatal 
diagnosis. Eur J Public Health. 2006;16:660-662.
 16. Prevalence of neural tube defects in 20 regions of 
Europe and the impact of prenatal diagnosis, 1980-1986. 
EUROCAT Working Group. J Epidemiol Community 
Health. 1991;45:52-58.
 17. Cragan JD, Roberts HE, Edmonds LD, et al. Surveillance 
for anencephaly and spina bifida and the impact of pre-
natal diagnosis—United States, 1985-1994. MMWR CDC 
Surveill Summ. 1995;44:1-13.
 18. Bower C, Raymond M, Lumley J, Bury G. Trends in neu-
ral tube defects 1980-1989. Med J Aust. 1993;158:152-
154.
 19. Rosano A, Smithells D, Cacciani L, et al. Time trends in 
neural tube defects prevalence in relation to preventive 
strategies: an international study. J Epidemiol Community 
Health. 1999;53:630-635.
 20. Gilbert NL., De Wals P, Leon JA, Evans JA. Congenital 
Anomalies in Canada 2013: Chapter 3: Neural Tube 
Defects. Vol 1. Ottawa, Ontario, Canada: Public Health 
Agency of Canada; 2013:119.
 21. Health Canada. A Perinatal Health Report, 2002. Vol 1. 
Ottawa, Ontario, Canada: Health Canada; 2002:1-87.
 22. Van Gelder MMHJ, Donders ART, Devine O, Roeleveld N, 
Reefhuis J; National Birth Defects Prevention Study. Using 
Bayesian models to assess the effects of under-reporting of 
Reece and Hulse 11
cannabis use on the association with birth defects, national 
birth defects prevention study, 1997-2005. Paediatr Perinat 
Epidemiol. 2014;28:424-433.
 23. Van Gelder MMHJ, Reefhuis J, Caton AR, Werler MM, 
Druschel CM, Roeleveld N. Maternal periconceptional 
illicit drug use and the risk of congenital malformations. 
Epidemiology. 2009;20:60-66.
 24. Degenhardt L, Ferrari AJ, Calabria B, et al. The global 
epidemiology and contribution of cannabis use and 
dependence to the global burden of disease: results from 
the GBD 2010 study. PLoS One. 2013;8:e76635.
 25. Whiteford HA, Degenhardt L, Rehm J, et al. Global bur-
den of disease attributable to mental and substance use 
disorders: findings from the Global Burden of Disease 
Study 2010. Lancet. 2013;382:1575-1586.
 26. Whiteford HA, Ferrari AJ, Degenhardt L, Feigin V, Vos 
T. The global burden of mental, neurological and sub-
stance use disorders: an analysis from the Global Burden 
of Disease Study 2010. PLoS One. 2015;10:e0116820.
 27. McCantz-Katz E. 2017 Annual Report Snippets, NSDUH, 
SAMHSA, USA DHHS—Selected Streamlined Trends. 
Vol 1. Rockville, MD: Substance Abuse and Mental 
Health Services; 2018.
 28. McCantz-Katz E. Urgent and emerging issues in preven-
tion: marijuana, kratom and E-cigarettes. https://www.
samhsa.gov/sites/default/files/samhsas_15th_annual_pre-
vention_day_afternoon_plenary_recording.pdf. Accessed 
November 28, 2019.
 29. Substance Abuse and Mental Health Services 
Administration. National Survey on Drug Use and 
Health (NSDUH). https://www.samhsa.gov/data/data-
we-collect/nsduh-national-survey-drug-use-and-health. 
Accessed November 28, 2019.
 30. Young-Wolff KC, Tucker L, Alexeeff S, et al. Trends 
in self-reported and biochemically tested marijuana use 
among pregnant females in California from 2009-2016. 
JAMA. 2017;318:2490-2491.
 31. Dickson B, Mansfield C, Guiahi M, et al. Recommendations 
from cannabis dispensaries about first-trimester cannabis 
use. Obstet Gynecol. 2018;131:1031-1038.
 32. Government of Canada. Canadian tobacco alcohol and 
drugs (CTADS): 2015 summary. https://www.canada.
ca/en/health-canada/services/canadian-tobacco-alcohol-
drugs-survey/2015-summary.html. Accessed November 
28, 2019.
 33. Statistics of Canada. Cannabis stats hub. https://www150.
statcan.gc.ca/n1/pub/13-610-x/cannabis-eng.htm. 
Accessed November 28, 2019.
 34. Statistics Canada. National Cannabis Survey, Second 
Quarter, 2018. https://www.facebook.com/StatisticsCanada/
posts/1636405843137586:0. Accessed November 28, 2019.
 35. Public Health Agency of Canada, Health Canada. Congenital 
anomalies in Canada, 2013: a perinatal health surveillance 
report. https://www.canada.ca/en/public-health/services/
health-promotion/what-is-ccasn/congenital-anomalies-
canada-2013-a-perinatal-health-surveillance-report.html. 
Accessed November 28, 2019.
 36. Leos-Toro C, Reid JL, Madill CL, Rynard VL, Manske 
SR, Hammond D. Tobacco use in Canada: patterns and 
trends. Special supplement: cannabis in Canada. https://
uwaterloo.ca/tobacco-use-canada/sites/ca.tobacco-use-
canada/files/uploads/files/cannabissupplement_2017_
final_accessible.pdf. Accessed November 28, 2019.
 37. Hilder L. Neural tube defects in Australia, 2007-2011: 
before and after implementation of mandatory folic acid 
fortification standard. https://npesu.unsw.edu.au/sites/
default/files/npesu/surveillances/NTD%20Australia%20
0711_1.pdf. Accessed November 28, 2019.
 38. Kilpatrick R. A primer on Nunavut, 5th edition. https://
www.nunavutcourts.ca/phocadownload/EN/Primer/
PrimerNunavut2015-2016.pdf. Accessed November 28, 
2019.
 39. Nunatsiaq News. Cannabis regulation: Nunavut must take its 
time. http://old.nunatsiaq.com/stories/article/65674cannabis_
regulation_nunavut_must_take_its_time/. Published April 
19, 2017. Accessed November 28, 2019.
 40. Hasin DS, Sarvet al, Cerda M, et al. US adult illicit 
cannabis use, cannabis use disorder, and medical mari-
juana laws: 1991-1992 to 2012-2013. JAMA Psychiatry. 
2017;74:579-588.
 41. Wang J, Yuan W, Li MD. Genes and pathways co-associ-
ated with the exposure to multiple drugs of abuse, includ-
ing alcohol, amphetamine/methamphetamine, cocaine, 
marijuana, morphine, and/or nicotine: a review of pro-
teomics analyses. Mol Neurobiol. 2011;44:269-286.
 42. Piatti E, Rizzi R, Re F, Chiesara E. Genotoxicity of 
heroin and cannabinoids in humans. Pharmacol Res. 
1989;21(suppl 1):59-60.
 43. Reece AS, Hulse GK. Chromothripsis and epigenomics 
complete causality criteria for cannabis- and addiction-
connected carcinogenicity, congenital toxicity and heri-
table genotoxicity. Mutat Res. 2016;789:15-25.
 44. Van Went GF. Mutagenicity testing of 3 hallucinogens: 
LSD, psilocybin and delta 9-THC, using the micronucleus 
test. Experientia. 1978;34:324-325.
 45. Tanveer R, Gowran A, Noonan J, Keating SE, Bowie 
AG, Campbell VA. The endocannabinoid, anandamide, 
augments Notch-1 signaling in cultured cortical neurons 
exposed to amyloid-beta and in the cortex of aged rats. J 
Biol Chem. 2012;287:34709-34721.
 46. Carlson BM. Human Embryology and Developmental 
Biology. Philadelphia, PA: Elsevier; 2014.
 47. Khaliullina H, Bilgin M, Sampaio JL, Shevchenko A, 
Eaton S. Endocannabinoids are conserved inhibitors 
of the Hedgehog pathway. Proc Natl Acad Sci U S A. 
2015;112:3415-3420.
 48. Birerdinc A, Jarrar M, Stotish T, Randhawa M, Baranova 
A. Manipulating molecular switches in brown adipocytes 
and their precursors: a therapeutic potential. Prog Lipid 
Res. 2013;52:51-61.
 49. Jung KM, Astarita G, Thongkham D, Piomelli D. 
Diacylglycerol lipase-alpha and -beta control neurite out-
growth in neuro-2a cells through distinct molecular mech-
anisms. Mol Pharmacol. 2011;80:60-67.
12 Global Pediatric Health
 50. Lee YS, Jeong WI. Retinoic acids and hepatic stellate cells 
in liver disease. J Gastroenterol Hepatol. 2012;27(suppl 
2):75-79.
 51. Mukhopadhyay B, Liu J, Osei-Hyiaman D, et al. 
Transcriptional regulation of cannabinoid receptor-1 
expression in the liver by retinoic acid acting via retinoic 
acid receptor-gamma. J Biol Chem. 2010;285:19002-19011.
 52. Fraher D, Ellis MK, Morrison S, et al. Lipid abundance in 
zebrafish embryos is regulated by complementary actions 
of the endocannabinoid system and retinoic acid pathway. 
Endocrinology. 2015;156:3596-3609.
 53. Alpar A, Tortoriello G, Calvigioni D, et al. Endocannabinoids 
modulate cortical development by configuring Slit2/Robo1 
signalling. Nat Commun. 2014;5:4421.
 54. Borrell V, Cardenas A, Ciceri G, et al. Slit/Robo signal-
ing modulates the proliferation of central nervous system 
progenitors. Neuron. 2012;76:338-352.
 55. Cardenas A, Villalba A, de Juan Romero C, et al. 
Evolution of cortical neurogenesis in amniotes controlled 
by robo signaling levels. Cell. 2018;174:590-606.e21.
 56. Vaz M, Hwang SY, Kagiampakis I, et al. Chronic cigarette 
smoke-induced epigenomic changes precede sensitization 
of bronchial epithelial cells to single-step transformation 
by KRAS mutations. Cancer Cell. 2017;32:360-376.e6.
 57. Anderson GR, Aoto J, Tabuchi K, et al. beta-neurexins 
control neural circuits by regulating synaptic endocan-
nabinoid signaling. Cell. 2015;162:593-606.
 58. Wang H. Endocannabinoid mediates excitatory synaptic 
function of β-neurexins. commentary: β-neurexins con-
trol neural circuits by regulating synaptic endocannabi-
noid signaling. Front Neurosci. 2016;10:203.
 59. Cutando L, Maldonado R, Ozaita A. Microglial activa-
tion and cannabis exposure. In: Preedy V, ed. Handbook 
of Cannabis and Related Pathologies: Biology, 
Pharmacology, Diagnosis and Treatment. New York, 
NY: Academic Press; 2017:401-412.
 60. Boulanger LM. Immune proteins in brain development 
and synaptic plasticity. Neuron. 2009;64:93-109.
 61. Carpentier PA, Palmer TD. Immune influence on 
adult neural stem cell regulation and function. Neuron. 
2009;64:79-92.
 62. DiNieri JA, Wang X, Szutorisz H, et al. Maternal canna-
bis use alters ventral striatal dopamine D2 gene regulation 
in the offspring. Biol Psychiatry. 2011;70:763-769.
 63. Murphy SK, Itchon-Ramos N, Visco Z, et al. Cannabinoid 
exposure and altered DNA methylation in rat and human 
sperm. Epigenetics. 2018;13:1208-1221.
 64. Zumbrun EE, Sido JM, Nagarkatti PS, Nagarkatti M. 
Epigenetic regulation of immunological alterations fol-
lowing prenatal exposure to marijuana cannabinoids and 
its long term consequences in offspring. J Neuroimmune 
Pharmacol. 2015;10:245-254.
 65. Chakraborty AA, Laukka T, Myllykoski M, et al. Histone 
demethylase KDM6A directly senses oxygen to control 
chromatin and cell fate. Science. 2019;363:1217-1222.
 66. Romero J, Garcia-Palomero E, Berrendero F, et al. 
Atypical location of cannabinoid receptors in white 
matter areas during rat brain development. Synapse. 
1997;26:317-323.
 67. Diaz-Alonso J, Guzman M, Galve-Roperh I. 
Endocannabinoids via CB(1) receptors act as neurogenic 
niche cues during cortical development. Philos Trans R 
Soc Lond B Biol Sci. 2012;367:3229-3241.
 68. Benyo Z, Ruisanchez E, Leszl-Ishiguro M, Sandor P, 
Pacher P. Endocannabinoids in cerebrovascular regulation. 
Am J Physiol Heart Circ Physiol. 2016;310:H785-H801.
 69. Aguado T, Monory K, Palazuelos J, et al. The endocan-
nabinoid system drives neural progenitor proliferation. 
FASEB J. 2005;19:1704-1706.
 70. Noonan MA, Eisch AJ. Regulation of adult neurogenesis 
by cannabinoids. Chemistry Today. 2006;24:84-88.
 71. Tan C, Lu NN, Wang CK, et al. Endothelium-derived 
semaphorin 3G regulates hippocampal synaptic struc-
ture and plasticity via neuropilin-2/plexinA4. Neuron. 
2019;101:920-937.e13.
 72. Bab IA. Regulation of skeletal remodeling by the endocan-
nabinoid system. Ann N Y Acad Sci. 2007;1116:414-422.
 73. Tam J, Trembovler V, Di Marzo V, et al. The cannabinoid 
CB1 receptor regulates bone formation by modulating 
adrenergic signaling. FASEB J. 2008;22:285-294.
 74. Hembree WC 3rd, Nahas GG, Zeidenberg P, Huang HF. 
Changes in human spermatozoa associated with high dose 
marihuana smoking. Adv Biosci. 1978;22-23:429-439.
 75. Huang HFS, Nahas GG, Hembree WC. Effects of mari-
juana inhalation on spermatogenesis of the rat. In: Nahas 
GG, Sutin KM, Harvey DJ, Agurell S, ed. Marijuana and 
Medicine. Totowa, NJ: Humana Press; 1999:359-366.
 76. Morishima A. Effects of cannabis and natural canna-
binoids on chromosomes and ova. NIDA Res Monogr. 
1984;44:25-45.
 77. Zimmerman AM, Zimmerman S, Raj AY. Effects of can-
nabinoids on spermatogenesis in mice. In: Nahas GG, 
Sutin KM, Harvey DJ, Agurell S, eds. Marihuana and 
Medicine. Totowa, NJ: Humana Press; 1999:347-358.
 78. Zimmerman AM, Bruce WR, Zimmerman S. Effects of 
cannabinoids on sperm morphology. Pharmacology. 
1979;18:143-148.
 79. Liu W, Komiya Y, Mezzacappa C, Khadka DK, Runnels 
L, Habas R. MIM regulates vertebrate neural tube closure. 
Development. 2011;138:2035-2047.
 80. Forrester MB, Merz RD. Risk of selected birth defects 
with prenatal illicit drug use, Hawaii, 1986-2002. J 
Toxicol Environ Health A. 2007;70:7-18.
 81. Morimoto S, Tanaka Y, Sasaki K, et al. Identification and 
characterization of cannabinoids that induce cell death 
through mitochondrial permeability transition in Cannabis 
leaf cells. J Biol Chem. 2007;282:20739-20751.
 82. Shoyama Y, Sugawa C, Tanaka H, Morimoto S. 
Cannabinoids act as necrosis-inducing factors in Cannabis 
sativa. Plant Signal Behav. 2008;3:1111-1112.
